ישראל - עברית - Ministry of Health

linevitz eliezer - tolfenamic acid 60 mg - tablets - treatment of acute inflammation due to chronic locomotor disease in dogs.

ישראל - עברית - Ministry of Health

tzamal medical ltd - רופא - בהתאם להוראות היצרן - לאטימת רקמת מוח וחוט השידרה

ישראל - עברית - Ministry of Health

tzamal medical ltd - רופא - בהתאם להוראות היצרן - לאטימת רקמת מוח וחוט השידרה

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - lidocaine as hydrochloride; methylprednisolone acetate - תרחיף להזרקה - lidocaine as hydrochloride 10 mg/ml; methylprednisolone acetate 40 mg/ml - methylprednisolone, combinations - lidocaine - depo-medrol with lidocaine is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - synovitis of osteoarthritis - rheumatoid arthritis - acute and subacute bursitis - acute gouty arthritis - epicondylitis - acute nonspecific tenosynovitis - post-traumatic osteoarthritis.

ישראל - עברית - Ministry of Health

עמוס גזית בע"מ - רופא - hip prosthesis implants are indicated for surgery procedures result of idiopathic arthrosis, hip displasies, femur head necrosis, post-traumatic arthrosis, loosened endo prosthesis, coxitis, morbus perthes,trochanter fixation problems

ישראל - עברית - Ministry of Health

cts chemical industries ltd - paroxetine as hydrochloride - טבליה - paroxetine as hydrochloride 30 mg - paroxetine - paroxetine - treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. treatment of symptoms and prevention of relapse of obsessive compulsive disorder (ocd). treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia.treatment of symptoms of social phobia. post traumatic stress disorder. generalised anxiety disorders.

ישראל - עברית - Ministry of Health

טבע מדיקל (שיווק) בע"מ - מומחה - measurement of cardiac output and fluid volumes

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.